Karen Luong  – Husch Blackwell

Karen is a founding member of the psychedelic law practice group at Husch Blackwell.  With over sixteen years of experience in product liability litigation focusing on toxic products, Karen has a unique perspective in the emerging area of psychedelic therapeutics. She keeps current on the academic and commercial research and drug discovery efforts in this rapidly changing field, such as the development of medicines for PTSD and treatment-resistant depression. Karen assists psychedelics clients in navigating and complying with complex regulatory issues and protecting and commercializing intellectual property. She has a particular focus on helping clients forecast and take steps to protect against potential claims for product liability.

While psychedelic drugs such as MDMA, psilocybin, LSD and DMT are currently federally illegal Schedule 1 substances, the FDA is currently overseeing Phase I, II and III studies exploring the potential therapeutic benefit of these drugs. Members of the Husch Blackwell psychedelic law team are closely following this progress and concurrent proposed state legislation in multiple jurisdictions, and are positioned to help clients navigate what will no doubt be highly complex and novel legal issues.

Alongside her psychedelics practice, Karen works with the firm’s Mass Tort Litigation team, taking high stakes product liability cases to trial for some of the world’s largest companies.  Manufacturers, construction companies, automotive manufacturers and retailers, insurers, contractors, suppliers and business owners are a few of the clients relying on Karen’s experience, counsel and defense. She is well versed in complex litigation involving toxic products, materials and chemicals. Karen regularly represents clients in state and federal court in matters of product liability, premises liability, personal injury and other complex allegations. She is known for her ability to defend client reputation along with the legal claims at hand.

Publications:

• Recent Developments in the Legal Landscape of Psychedelic Therapeutics – https://microdose.buzz/news/195531/
• Speaking Engagement: “FDA regulatory guidance,” 2022 Psychedelic Therapeutic & Drug Development Conference – https://www.huschblackwell.com/newsandinsights/speaker-fda-regulatory-guidance-2022-psychedelic-therapeutics-drug-development-conference

Social Media:

• LinkedIn